Is there a place for CMV hyperimmune globulins in the treatment of CMV disease?

Abstract

A 59-year-old female patient, who was cytomegalovirus (CMV)IgG-negative, received a renal transplant from a CMV IgG-positivedonor in May 2007. She received triple drug treatment (tacrolimus,low dose sirolimus and corticosteroids) as immunosuppressant andwas treated for a Banff 2A rejection with a 10-day course of anti-thymocyte globulin (ATG) from day 10 onwards. Because the CMVserology of the donor originally was reported to be negative, no CMV prophylaxis was started. Due to detectable CMV viral loads inplasma (4.5 × 10e